Formulation and evaluation of a particulate oral breast cancer vaccine

Journal of Pharmaceutical Sciences

Volumn 101, Issue 10, 2012, Pages 3661-3671

  Chablani, Lipika ^a   Tawde, Suprita A ^a   Akalkotkar, Archana ^a   D'Souza, Cherilyn ^a   Selvaraj, Periasamy ^b   D'Souza, Martin J ^a  

^a MERCER UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Cyclodextrins; Microparticles; Spray drying; Vaccine delivery; Vaccines; Whole cell lysate

Indexed keywords

CANCER VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ARTICLE; BREAST CANCER; CANCER CELL; CD4 LYMPHOCYTE COUNT; CELL LYSATE; CONTROLLED STUDY; DRUG FORMULATION; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IN VITRO STUDY; MOUSE; NONHUMAN; SUSTAINED DRUG RELEASE; T LYMPHOCYTE; TUMOR GROWTH;

EID: 84865363407     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23275     Document Type: Article

References (42)

1. World Health Organization-Breast Cancer Awareness Month. Accessed April 30, 2012, at: http://www.who.int/cancer/detection/breastcancer/en/index1.html.
2. Mittendorf EA, Alatrash G, Xiao H, Clifton GT, Murray JL, Peoples GE. 2011. Breast cancer vaccines: Ongoing National Cancer Institute-registered clinical trials. Expert Rev Vaccines 10(6):755-774.
3. Curigliano G, Locatelli M, Fumagalli L, Goldhirsch A. 2009. Immunizing against breast cancer: A new swing for an old sword. Breast 18(Suppl 3):S51-S54.
4. + breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial. J Am Coll Surg 210(2):140-147.
5. Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R. 2007. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: Results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol 25(24):3680-3687.
6. Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA, Sims RB, Lin LR, Frohlich MW, Park JW. 2009. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res 15(18):5937-5944.
7. Mittendorf EA, Holmes JP, Ponniah S, Peoples GE. 2008. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother 57(10):1511-1521.
8. Pulendran B, Banchereau J, Maraskovsky E, Maliszewski C. 2001. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 22(1):41-47.
9. NeuVax-Galenpharma pipeline. Accessed March 7, 2012, at: http://www.galenabiopharma.com/pipeline.
10. Pickard JM, Chervonsky AV. 2010. Sampling of the intestinal microbiota by epithelial M cells. Curr Gastroenterol Rep 12(5):331-339.
11. D'Souza B, Bhowmik T, Shashidharamurthy R, Oettinger C, Selvaraj P, D'Souza M. 2011. Oral microparticulate vaccine for melanoma using M-cell targeting. J Drug Target 20(2):166-173.
12. Malik B, Goyal AK, Mangal S, Zakir F, Vyas SP. 2010. Implication of gut immunology in the design of oral vaccines. Curr Mol Med 10(1):47-70.
13. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. 2012. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 132(2):545-553.
14. Chin CS, Bear HD. 2002. Sentinel node mapping identifies vaccine-draining lymph nodes with tumor-specific immunological activity. Ann Surg Oncol 9(1):94-103.
15. Gravekamp C, Sypniewska R, Hoflack L. 2004. The usefulness of mouse breast tumor models for testing and optimization of breast cancer vaccines at old age. Mech Ageing Dev 125(2):125-127.
16. Heppner GH, Miller FR, Shekhar PM. 2000. Nontransgenic models of breast cancer. Breast Cancer Res 2(5):331-334.
17. + T cell responses induced by a single injection of a HIV DNA vaccine in mice. J Immunol 178(4):2318-2327.
18. Parviz M, Chin CS, Graham LJ, Miller C, Lee C, George K, Bear HD. 2003. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model. Cancer Immunol Immunother 52(12):739-750.
19. Chiang CL, Benencia F, Coukos G. 2010. Whole tumor antigen vaccines. Semin Immunol 22(3):132-143.
20. Solbrig CM, Saucier-Sawyer JK, Cody V, Saltzman WM, Hanlon DJ. 2007. Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor cells. Mol Pharm 4(1):47-57.
21. Estevan M, Irache JM, Grillo MJ, Blasco JM, Gamazo C. 2006. Encapsulation of antigenic extracts of Salmonella enterica serovar. Abortusovis into polymeric systems and efficacy as vaccines in mice. Vet Microbiol 118(1-2):124-132.
22. Akande J, Yeboah KG, Addo RT, Siddig A, Oettinger CW, D'Souza MJ. 2010. Targeted delivery of antigens to the gut-associated lymphoid tissues: 2. Ex vivo evaluation of lectin-labelled albumin microspheres for targeted delivery of antigens to the M-cells of the Peyer's patches. J Microencapsul 27(4):325-336.
23. Tuohy VK, Jaini R. 2011. Prophylactic cancer vaccination by targeting functional non-self. Ann Med 43(5):356-365.
24. Tuohy VK. 2010. A prophylactic vaccine for breast cancer? Why not? Breast Cancer Res 12(6):405.
25. Jaini R, Kesaraju P, Johnson JM, Altuntas CZ, Jane-Wit D, Tuohy VK. 2010. An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat Med 16(7):799-803.
26. Bhowmik T, D'Souza B, Uddin MN, D'Souza MJ. 2012. Oral delivery of microparticles containing plasmid DNA encoding hepatitis-B surface antigen. J Drug Target 20(4):364-371.
27. Gayakwad SG, Bejugam NK, Akhavein N, Uddin NA, Oettinger CE, D'Souza MJ. 2009. Formulation and in vitro characterization of spray-dried antisense oligonucleotide to NF-kappaB encapsulated albumin microspheres. J Microencapsul 26(8):692-700.
28. Uddin AN, Bejugam NK, Gayakwad SG, Akther P, D'Souza MJ. 2009. Oral delivery of gastro-resistant microencapsulated typhoid vaccine. J Drug Target 17(7):553-560.
29. Uddin MN, Do DP, Pai SB, Gayakwad S, Oettinger CW, D'Souza MJ. 2009. A methodology for quantitation and characterization of oligonucleotides in albumin microspheres. Analyst 134(7):1483-1489.
30. Yeboah KG, D'Souza MJ. 2009. Evaluation of albumin microspheres as oral delivery system for Mycobacterium tuberculosis vaccines. J Microencapsul 26(2):166-179.
31. Lai YH, D'Souza MJ. 2007. Formulation and evaluation of an oral melanoma vaccine. J Microencapsul 24(3):235-252.
32. Chablani L, Tawde SA, D'Souza MJ. 2012. Spray-dried microparticles: a potential vehicle for oral delivery of vaccines. J Microencapsul 29(4):388-397.
33. Do DP, Pai SB, Rizvi SA, D'Souza MJ. 2010. Development of sulforaphane-encapsulated microspheres for cancer epigenetic therapy. Int J Pharm 386(1-2):114-121.
34. Manmohan S. 2007. Vaccine adjuvants and delivery systems. Hoboken, New Jersey: Wiley-Interscience, pp 223-247.
35. Roth-Walter F, Bohle B, Scholl I, Untersmayr E, Scheiner O, Boltz-Nitulescu G, Gabor F, Brayden DJ, Jensen-Jarolim E. 2005. Targeting antigens to murine and human M-cells with Aleuria aurantia lectin-functionalized microparticles. Immunol Lett 100(2):182-188.
36. Brayden DJ. 2001. Oral vaccination in man using antigens in particles: Current status. Eur J Pharm Sci 14(3):183-189.
37. O'Hagan DT. 1994. Novel delivery systems for oral vaccines. Boca Raton, Florida: CRC Press, pp 175-205.
38. Goldsby RA. 2003. Immunology. 5th ed. New York: W.H. Freeman, p 556.
39. Carcaboso AM, Hernandez RM, Igartua M, Rosas JE, Patarroyo ME, Pedraz JL. 2004. Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine 22(11-12):1423-1432.
40. Malik B, Goyal AK, Markandeywar TS, Rath G, Zakir F, Vyas SP. 2012. Microfold-cell targeted surface engineered polymeric nanoparticles for oral immunization. J Drug Target 20(1):76-84.
41. Marzo AL, Lake RA, Robinson BW, Scott B. 1999. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 59(5):1071-1079.
42. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, Matzinger P. 2007. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109(12):5346-5354.